Broadcom Inc. (AVGO)

Broadcom's stock closed up 8.78% in the latest session at $319.48, but it remains 35.46% below its 52-week high of $495.00 and sits 14% of the way up its 52-week range. The rebound comes after a weak stretch: the stock is down 24.37% over three months and 25.43% over six months, and it trades below both its 50-day average ($346.90) and its 200-day average ($367.09). The main question for investors is whether a one-session jump can turn into a sustained repair of a trend that still points down. The fundamentals are strong, and analysts are notably more positive than the price. Revenue grew 85.50% year on year in the latest quarter, the stock's net profit margin is 42.94%, and 49 of 51 analysts rate it Buy or Strong Buy. Against that, the trailing P/E of 40.80 is 16.2% above the sector median, and the CleaRank rating is Hold, a score of 59 out of 100.

Broadcom rose 8.78% in its latest session, on volume 27.9% above its average, but the move has not yet changed the larger picture. The stock is still below its 20-day EMA's neighbours at the 50-day and 200-day averages, and the MACD line is negative. The RSI of 44.7 sits in the neutral zone, which means momentum is recovering from weak levels rather than showing strength. One day of heavy buying is a start, but it needs follow-through above the moving averages before it counts as a trend change.

Revenue grew 85.50% year on year in the latest quarter, against a sector median of 24.2%, and the net profit margin of 42.94% and operating margin of 54.31% are both high. Return on equity of 44.25% is well above the sector median of 13.4%, and the debt-to-equity ratio of 0.60 leaves the balance sheet in good shape. These figures earn the stock a premium: its trailing P/E of 40.80 is 16.2% above the sector median of 35.1, and its price-to-sales ratio of 17.12 is 125.3% above the sector median of 7.6. The valuation is high, but it is backed by growth that far outpaces the sector.

Broadcom has beaten the EPS estimate in all eight of the most recent reports, the latest on September 2, 2026, when EPS of $3.32 topped the $3.24 estimate by 2.47%. Yet the share price fell 2.74% in the first session after that report, and it also fell in four of the eight post-beat sessions on record. The June 3, 2026 report produced the largest reaction in this set: a 12.59% decline in the first session despite a beat. Investors are clearly weighing guidance and expectations as much as the headline figure.

Of 51 analysts, 49 rate the stock Buy or Strong Buy, two rate it Hold, and none rate it Sell. On October 27, 2026, Rosenblatt kept its Buy rating and DA Davidson upgraded the stock to Buy from Neutral. Tigress Financial started coverage at Buy on October 22, 2026, and Piper Sandler started at Overweight on September 10, 2026. Three months ago, 45 of 49 ratings were Buy. CleaRank's Hold rating is more cautious than the Street's Buy consensus, reflecting the weight it places on the trend and the valuation.

The base case is a stock that stays range-bound and volatile while it works back above its moving averages. Revenue growth and margins give the analysts' forecasts something to rest on: they expect EPS to rise 71.1% in this fiscal year and 66.9% in the year after. For the price to recover, it first needs to reclaim the 20-day EMA at $328.95 and then the 50-day SMA at $346.90; holding above those levels would show that the recent bounce has support. The analysts' median 12-month target of $535.00 sits 67.5% above the current price, and the range of targets runs from $400.00 to $660.00, so the Street's view depends on earnings delivery. The main risks are on the other side of the ledger. The stock has a beta of 1.51 and a typical daily move of 3.59%, so sharp swings in either direction are normal. Insider selling totalled $1.2B over the last 18 months, against $1.9M of open-market purchases, and the stock fell after several recent reports even when earnings beat estimates: it dropped in four of the eight most recent first sessions after a beat. A weaker outcome would be a failure to hold the 52-week low at $289.77 or a sell-off after the next earnings report.

Support sits at the 52-week low of $289.77, the only level below the price; a fall to that point would take the stock back to the bottom of its yearly range. Resistance comes first at the 20-day EMA of $328.95, the average that the price has just moved above, followed by the 50-day SMA at $346.90, which the stock has been trading below for the recent weeks. Above that, the 200-day SMA at $367.09 is the next test, and the 52-week high of $495.00 is the far ceiling.